Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Biophytis S.A.

Company price
0.4 USD 0.00(0%)
Last update at 2026-11-18T14:30:00Z
Market Cap
4.58M

Momentum Score

…

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.40
Low
0.40
High
52 Week Price Range
0.00
Low
3.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biophytis S.A. is a clinical-stage biotechnology company developing small-molecule therapies targeting age-related muscle weakness and respiratory disorders, with lead programs aimed at improving muscle and lung function. Long-term growth may be supported by demographic trends toward older populations, persistent unmet needs in sarcopenia and pulmonary disease, and advancement through clinical and regulatory milestones. Investors may find exposure to potentially high-impact clinical outcomes and a focused therapeutic niche attractive, while acknowledging binary program outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.40
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-1.02
ROE
-
Net Debt
9.76M
ROCE
97.63%
Diluted EPS TTM
-3.99

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -10.38M -18.59M -24.22M -31.25M -17.05M
Minority interest 0.00M 0.00M 0.00M 0.00M 0.00M
Net income -10.38M -17.03M -24.22M -31.16M -25.52M
Selling general administrative 5.12M 5.49M 7.24M 7.15M 4.02M
Selling and marketing expenses - 0.42M 0.14M 0.93M 0.24M
Gross profit 0.00M -0.80M -0.48M -0.31M -0.28M
Reconciled depreciation 0.30M 0.80M 0.48M 0.31M 0.28M
Ebit -8.50M -14.33M -23.52M -26.82M -13.94M
Ebitda -8.26M -13.80M -23.04M -26.50M -13.66M
Depreciation and amortization 0.24M 0.53M 0.48M 0.31M 0.28M
Operating income -8.50M -14.33M -23.27M -26.82M -13.94M
Other operating expenses 8.50M 14.33M 23.27M 26.82M 13.94M
Interest expense 1.53M 1.25M 1.60M 4.43M 4.37M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -1.33M -1.41M -2.46M -2.53M -1.50M
Income tax expense - -1.56M -1.52M 2.28M 4.37M
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses 8.50M 14.33M 23.27M 26.82M 13.94M
Cost of revenue 0.00M 0.80M 0.48M 0.31M 0.28M
Total other income expense net -1.89M -4.25M -0.94M -4.35M -11.57M
Net income from continuing ops -10.38M -17.03M -24.22M -31.16M -25.52M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 6.90M 11.96M 21.99M 36.26M 27.21M
Intangible assets 2.61M 2.64M 2.65M 2.76M 2.67M
Other current assets 3.85M 0.18M 2.16M 1.42M 5.66M
Total liab 16.60M 15.85M 23.90M 30.56M 20.38M
Total stockholder equity -9.67M -3.86M -1.88M 5.74M 6.86M
Other current liab 6.52M 3.36M 2.10M 4.83M 6.23M
Common stock 0.73M 2.08M 47.66M 27.19M 20.15M
Capital stock 0.73M 2.08M 47.66M 27.19M 20.15M
Retained earnings -10.38M -19.38M -47.91M -49.11M -17.05M
Other assets - 0.02M 0.00M 0.00M -
Cash 0.08M 5.57M 11.05M 23.93M 5.85M
Total current liabilities 15.61M 12.37M 19.35M 23.14M 18.36M
Current deferred revenue - 0.18M 0.18M 0.17M 0.01M
Net debt 9.76M 0.51M 1.07M -8.55M 3.25M
Short term debt 9.09M 3.52M 10.21M 8.37M 7.26M
Short long term debt 6.48M 3.47M 7.48M 8.15M 10.81M
Short long term debt total 9.84M 6.08M 12.13M 15.38M 9.10M
Other stockholder equity 15.28M 13.47M -1.61M 27.83M 42.90M
Total current assets 3.92M 8.85M 18.58M 31.69M 24.01M
Long term investments 0.01M 0.03M 0.04M 0.07M 0.09M
Short term investments 0.19M 0.37M 0.59M 1.23M 12.92M
Net receivables 0.08M 2.74M 5.20M 5.12M 5.21M
Long term debt - 2.42M 3.51M 4.39M 0.94M
Inventory - 0.00M 1.57M -0.71M 0.03M
Accounts payable 4.28M 5.35M 6.94M 7.61M 7.99M
Accumulated other comprehensive income -15.30M -0.03M -0.03M -0.07M -14.01M
Non currrent assets other 0.14M 0.13M 0.12M 1.17M 0.32M
Non current assets total 2.98M 3.11M 3.41M 4.57M 3.20M
Capital lease obligations 0.14M 0.19M 0.47M 0.45M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.37M -0.02M 12.16M -12.71M
Total cashflows from investing activities 0.01M - - - -
Net borrowings 4.00M - - - -
Total cash from financing activities 3.14M 7.03M 6.13M 29.71M 22.07M
Net income -10.38M -17.03M -24.22M -31.25M -17.05M
Change in cash -5.49M -5.49M -12.87M 18.08M -0.49M
Begin period cash flow 5.57M 11.05M 23.93M 5.85M 6.34M
End period cash flow 0.08M 5.57M 11.05M 23.93M 5.85M
Total cash from operating activities -8.64M -12.87M -18.99M -23.80M -9.86M
Issuance of capital stock - 5.54M 0.00M 16.58M 23.49M
Depreciation 1.06M 0.80M 0.48M 0.31M 0.28M
Other cashflows from investing activities 0.01M - - - -
Dividends paid - 0.00M 0.00M 0.00M 0.00M
Change to inventory - - 0.40M 1.30M -2.65M
Change to account receivables -1.36M 1.67M -0.40M -1.30M 2.65M
Other cashflows from financing activities -0.09M 1.14M -1.29M 12.84M -6.17M
Capital expenditures 0.00M 0.22M 0.14M 0.34M 0.21M
Change in working capital -1.36M -0.03M -1.33M 1.32M 3.01M
Stock based compensation 0.74M 0.81M 5.57M 3.42M 0.79M
Other non cash items 1.30M 2.56M 0.51M 0.48M 4.52M
Free cash flow -8.64M -13.09M -19.13M -24.14M -10.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BPTSY
Biophytis S.A.
-
-%
0.40 - - - 2.27 -0.42
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Biophytis S.A.

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.

14 avenue de l'Opéra, Paris, France, 75001

33 1 44 27 23 00

19

Name Title Year Born
Mr. Stanislas Veillet Ph.D. Chairman of the Board & CEO 1965
Mr. Waly Dioh Ph.D. Chief Clinical Operating Officer 1969
Dr. Pierre J. Dilda Ph.D. Chief Scientific Officer 1970
Dr. Rene Lafont Scientific Advisor & Member of Scientific Advisory Board 1946
Dr. Rob van Maanen FFPM, M.B.A., M.D. Chief Medical Officer 1971
Mr. Edouard Bieth Chief Business Officer 1980
Ms. Chiara Baccelli Chief Pharmaceutical Operations Officer & Quality Assurance Director NA
Ms. _ Teylan Financial Controller NA
Mr. Christophe Courtillat Chief Financial Officer NA
Mr. Waly Dioh Ph.D. Chief Operating Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…